INTEGRA ANNOUNCES SUBMISSION OF REVISED DELAMAR MINE PLAN OF OPERATIONS AND APPOINTS U.S. AIR FORCE LIEUTENANT GENERAL (RET.) LEONARD KOSINSKI AS BOARD ADVISOR

PR Newswire

TSXV: ITR; NYSE American: ITRG


www.integraresources.com


VANCOUVER, BC
, April 2, 2025 /PRNewswire/ – Integra Resources Corp. (“Integra” or the “Company”) (TSXV: ITR) (NYSE American: ITRG) is pleased to announce the formal submission of the updated Mine Plan of Operations (“MPO”) to the U.S. Bureau of Land Management (“BLM”) for the DeLamar Project (“DeLamar”) located in southwestern Idaho, United States (“U.S.”). This important regulatory milestone marks the initiation of the federal permitting process under the National Environmental Policy Act (“NEPA”) and represents a major achievement in the advancement of DeLamar.

In parallel with the submission of the MPO, Integra is pleased to announce the appointment of U.S. Air Force Lieutenant General, 3-star, (Ret.) Leonard “Leo” Kosinski as a strategic Board Advisor. General Kosinski brings over three decades of high-ranking military, governmental, and international leadership experience that will support the Company’s growing engagement with federal stakeholders as permitting and development activities accelerate at DeLamar.

Integra would also like to recognize the Executive Order (“EO”) published by the federal administration on March 20, 2025, titled “Immediate Measures to Increase American Mineral Production”. The EO calls for streamlined permitting timelines, enhanced federal permitting coordination, and strategic investment into domestic mineral supply chains. Continued government support for domestic minerals projects comes at a crucial time for Integra as federal permitting efforts officially begin for DeLamar.

George Salamis, President, CEO and Director of Integra commented: “The submission of the updated MPO is a crucial moment for Integra and the future of the DeLamar gold-silver project in Idaho. This marks the official start of the federal mine permitting process and demonstrates our commitment to advancing DeLamar in a responsible, transparent, and timely manner. We believe the enhanced project design reflected in the MPO positions Integra as a leading candidate to benefit from the evolving, progressive, and supportive permitting landscape that is occurring at both federal and state levels. At this time we are also extremely honored to welcome Lieutenant General Kosinski as an advisor to the Company. His deep experience in U.S. federal operations, relationships with senior levels of government, and direct insights into energy security and industrial base resilience will be invaluable as we advance DeLamar through permitting over the next two years. We are thrilled to have Leo on board and look forward to the guidance he will bring as we align our project with national priorities in the U.S.”

Updated MPO Submission: A Major Step Forward for DeLamar

The submission of the updated MPO to the BLM initiates the pathway to the issuance of a Notice of Intent (“NOI”), which is a formal announcement of BLM’s intent to prepare an Environmental Impact Statement (“EIS”) to evaluate the potential environmental effects of the proposed action. The NOI is followed by a scoping process which includes engagement with federal, state, and local agencies and the general public. Once the EIS is formally scoped, the BLM will conduct environmental impact analysis for the proposed action as well as reasonable alternatives to the proposed action. Through this alternatives evaluation process, refinements to the MPO may be identified that reduce environmental impacts. A Draft EIS (“DEIS”) will publish the results of BLM’s environmental analysis and will be open to public comment for a minimum of 45 days. Public comments on the DEIS will be addressed by the BLM in the Final EIS (“FEIS”) and accompanying Record of Decision document, which may include BLM-proposed measures to mitigate environmental impacts. The BLM’s environmental analysis under NEPA (NOI to FEIS) is anticipated to span two years, and is a rigorous, transparent, and prescriptive permitting framework that guides federal review of mining projects on public lands. Federal permitting will be complemented by a host of equally robust permits from multiple Idaho state agencies that serve to protect the quality of Idaho’s air, water, and land.

Integra’s updated MPO for DeLamar reflects a significantly optimized and environmentally enhanced mine plan, including a more compact project footprint and design modifications aimed at reducing projected carbon emissions and water usage. These improvements were developed through extensive technical analysis, stakeholder engagement, and a focus on the integration of modern sustainable mining practices.

Appointment of Lieutenant General (Ret.) Leonard Kosinski as Board Advisor

To strengthen Integra’s federal government engagement and strategic advisory capacity during this critical permitting period, the Company is pleased to welcome Lieutenant General (Ret.) Leo Kosinski as a Strategic Board Advisor.

General Kosinski recently served as Director for Logistics on the Joint Staff at the U.S. Department of Defense and the Pentagon, where he oversaw global logistics, energy and climate planning, deployment operations, and industrial base coordination. His prior roles include Deputy Commander of U.S. Air Forces Japan and Director of Logistics for U.S. Africa Command, where he was responsible for operations across 53 nations. With over 31 years of military and international leadership experience, including multiple postings in Washington D.C., Europe, and Asia, General Kosinski brings a wealth of knowledge in navigating complex government environments, executing strategic infrastructure projects, and advancing policy goals across multiple agencies.

The addition of General Kosinski brings immense and immediate strategic benefit to the Company as federal permitting begins for DeLamar.

Immediate Measures to Increase American Mineral Production Executive Order

Integra welcomes the recent EO signed by the federal administration, on March 20, 2025. The EO titled “Immediate Measures to Increase American Mineral Production” calls for accelerated permitting timelines, enhanced federal permitting coordination, and strategic investment into domestic mineral supply chains. As stated in the EO, permitting bottlenecks for upstream resource projects represent a national security and economic risk that must be addressed immediately. The EO targets specific initiatives including streamlining permitting, re-evaluating land access, clarifying the Mining Act, mobilizing capital, and strategic stockpiling and procurement for domestic minerals.

Additional details on the recently signed EO can be found on the official White House website: https://www.whitehouse.gov/presidential-actions/2025/03/immediate-measures-to-increase-american-mineral-production/

About Integra Resources

Integra is a growing precious metals producer in the Great Basin of the Western United States. Integra is focused on demonstrating profitability and operational excellence at its principal operating asset, the Florida Canyon Mine, located in Nevada. In addition, Integra is committed to advancing its flagship development-stage heap leach projects: the past producing DeLamar Project located in southwestern Idaho and the Nevada North Project located in western Nevada. Integra creates sustainable value for shareholders, stakeholders, and local communities through successful mining operations, efficient project development, disciplined capital allocation, and strategic M&A, while upholding the highest industry standards for environmental, social, and governance practices.

ON BEHALF OF THE BOARD OF DIRECTORS

George Salamis
President, CEO and Director

Forward Looking and Other Cautionary Statements

Certain information set forth in this news release contains “forward‐looking statements” and “forward‐looking information” within the meaning of applicable Canadian securities legislation and applicable United States securities laws (referred to herein as forward‐looking statements). Except for statements of historical fact, certain information contained herein constitutes forward‐looking statements which includes, but is not limited to, statements with respect to: the NOI to FEIS process and expected timelines; the anticipated benefits of the appointment of the Board advisor; the anticipated benefits of the EO; the future financial or operating performance of the Company and the Company’s mineral properties and project portfolio; the results from work performed to date; the estimation of mineral resources and reserves; the realization of mineral resource and reserve estimates; the development, operational and economic results of technical reports on mineral properties referenced herein; magnitude or quality of mineral deposits; the anticipated advancement of the Company’ mineral properties and project portfolios; exploration expenditures, costs and timing of the development of new deposits; underground exploration potential; costs and timing of future exploration; the completion and timing of future development studies; estimates of metallurgical recovery rates; exploration prospects of mineral properties; requirements for additional capital; the future price of metals; government regulation of mining operations; environmental risks; the timing and possible outcome of pending regulatory matters; the realization of the expected economics of mineral properties; future growth potential of mineral properties; and future development plans.

Forward-looking statements are often identified by the use of words such as “may”, “will”, “could”, “would”, “anticipate”, “believe”, “expect”, “intend”, “potential”, “estimate”, “budget”, “scheduled”, “plans”, “planned”, “forecasts”, “goals” and similar expressions. Forward-looking statements are based on a number of factors and assumptions and necessarily involve known and unknown risks and uncertainties, which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or result expressed or implied by such forward‐looking statements. Readers are advised to study and consider risk factors disclosed in Integra’s Annual Information Form dated March 26, 2025 for the fiscal year ended December 31, 2024, which is available on the SEDAR+ issuer profile for the Company at www.sedarplus.ca and available as Exhibit 99.1 to Integra’s Form 40-F, which is available on the EDGAR profile for the Company at www.sec.gov.

There can be no assurance that forward‐looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. The Company undertakes no obligation to update forward‐looking statements if circumstances or management’s estimates or opinions should change except as required by applicable securities laws. The forward-looking statements contained herein are presented for the purposes of assisting investors in understanding the Company’s plans, objectives and goals, and may not be appropriate for other purposes. Forward-looking statements are not guarantees of future performance and the reader is cautioned not to place undue reliance on forward‐looking statements.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/integra-announces-submission-of-revised-delamar-mine-plan-of-operations-and-appoints-us-air-force-lieutenant-general-ret-leonard-kosinski-as-board-advisor-302417613.html

SOURCE Integra Resources Corp.

Trilogy Metals Reports First Quarter Fiscal 2025 Financial Results

PR Newswire


VANCOUVER, BC
, April 2, 2025 /PRNewswire/ – Trilogy Metals Inc. (TSX: TMQ) (NYSE American: TMQ) (“Trilogy Metals” or the “Company”) announces its financial results for the first quarter ended February 28, 2025. Details of the Company’s financial results are contained in the interim unaudited consolidated financial statements and Management’s Discussion and Analysis which will be available on the Company’s website at www.trilogymetals.com, on SEDAR+ at www.sedarplus.ca and on EDGAR at www.sec.gov. All amounts are in United States dollars unless otherwise stated.

Selected Results

The following selected financial information is prepared in accordance with U.S. GAAP.


in thousands of dollars,

except for per share amounts


Three months ended


Selected expenses


February 28,
2025


$


February 29,
2024


$

General and administrative

343

415

Investor relations

16

12

Professional fees

447

200

Salaries

207

191

Salaries and directors expense – stock-based compensation

2,230

1,999

Total expenses

3,232

2,820

Share of loss on equity investment

581

793

Comprehensive loss for the period

(3,623)

(3,601)

Basic and diluted loss per common share

(0.02)

(0.02)

For the three-month period ended February 28, 2025, we reported a net loss of $3.6 million comparable to a net loss of $3.6 million for the three-month period ended February 29, 2024. Comparing the first quarter of 2025 to first quarter of 2024, there was an increase of $0.2 million in professional fees due to increased consulting and legal fees related to the Bornite preliminary economic assessment technical report and the Company’s Base Shelf Prospectus filing, offset by a decrease of $0.2 million in our share of losses of Ambler Metals LLC (“Ambler Metals”) due to reduction in activities at the Ambler Access Project (as defined below).

Corporate and Project Activities

Bornite PEA

On January 15, 2025, the Company announced the positive results of its Preliminary Economic Assessment Study (“Bornite PEA”) for the Bornite copper project. Highlights of the Bornite PEA include the following:

  • 1.9 billion pounds of copper over 17-year mine life;
  • Potential to extend mine activity for the Upper Kobuk Mineral Projects to over 30 years;
  • Pre-tax net present value (“NPV”)8% of $552.0 million and an internal rate of return (“IRR”) of 23.6%; and
  • After-tax NPV8% of $394.0 million and after-tax IRR of 20.0%.

The Bornite PEA describes the technical and economic viability of establishing an underground mining operation for a 6,000 tonne-per-day operation with a 17-year mine life. The Bornite PEA assumes re-purposing the infrastructure described in the Company’s current Feasibility Study for the Arctic Project for the use with the Bornite Project once the Arctic deposit has been depleted. More information on the Arctic Feasibility Study and the Bornite PEA can be accessed on the Company’s website at www.trilogymetals.com.

Budget -Trilogy

The Company has a 2025 fiscal year cash budget totaling $3.1 million. For the three-month period ended February 28, 2025, we used $0.8 million in operating activities mainly for personnel costs, professional fees, regulatory and office expenses compared with budgeted cash expenditures totaling $1.0 million

Budget – Ambler Metals LLC

The board of Ambler Metals approved a 2025 fiscal year budget totaling $5.8 million to support external and community affairs, to maintain the State of Alaska mineral claims in good standing, and for the maintenance of physical assets. During the three-month period ended February 28, 2025, Ambler Metals expended $1.2 million on salaries and wages, professional fees, engineering, project support costs and mineral property expenses, and the Ambler Access Project costs mainly for subsistence committee meetings and community relations, compared with the budget of $1.0 million.

Ambler Mining District Industrial Access Project (“Ambler Access Project” or “Ambler Road”)

On January 20, 2025, President Trump signed a comprehensive executive order titled “Unleashing Alaska’s Extraordinary Resource Potential”, instructing agency heads across the federal government to revoke, rescind or revise regulations that are inconsistent with resource development in Alaska, including those issued by former President Biden when he was in office.

It places a moratorium on all activities related to the rejection of a right-of-way permit to build the Ambler Road and directs the reinstatement of the prior Trump Administration’s 2020 approval of the right-of-way permit to build the Ambler Road.

The order was broadly welcomed by Alaska’s political leaders, including Senators Dan Sullivan and Lisa Murkowski, and Representative Nick Begich.

Department of Interior Secretary Doug Burgum subsequently signed a series of secretarial orders, echoing the executive orders signed by President Trump. Secretary Burgum’s Order 3422 on February 3, 2025, also titled “Unleashing Alaska’s Extraordinary Resource Potential”, directs the submission of an action plan to him that includes “steps to expedite the permitting and leasing of energy and natural resource projects in Alaska (including the rights-of-way and easements for roads that enable this development to occur).”

On March 20, 2025, President Trump signed an executive order titled “Immediate Measures to Increase American Mineral Production”, which underscores the importance of securing a stable and predictable domestic supply of critical minerals (including copper and gold) that are essential for the nation’s defense, technology, and infrastructure, and to reduce the reliance on foreign imports. The order directs federal agencies to expedite approvals for mineral production projects.

Also on March 20, 2025, Secretary Burgum announced that the Bureau of Land Management will work towards partial revocation of public land withdrawals to convey these lands to the State of Alaska. This action is expected to help advance the Ambler Road.

Secretary Burgum’s announcement was commended by Alaska Senators Sullivan and Murkowski, and Representative Begich in a joint statement on March 20, 2025.

Liquidity and Capital Resources

We expended $0.7 million on operating activities during the three-month period ending February 28, 2025 with the majority of cash spent on professional fees to complete the Bornite preliminary economic assessment and related technical reports and American and Canadian securities commission fees related to our annual regulatory filings, annual fees paid to the Toronto Stock Exchange and the NYSE American Exchange and corporate salaries.

As at February 28, 2025, we had $25.2 million in cash and cash equivalents and working capital (current assets less current liabilities) of $24.6 million. There is sufficient cash on hand to fund the approved fiscal 2025 budget of $3.1 million.

All project related costs are funded by Ambler Metals. Ambler Metals had $6.5 million in cash and cash equivalents and $6.4 million in working capital as at February 28, 2025. There are sufficient funds at Ambler Metals to fund this fiscal year’s approved budget of $5.8 million

Qualified Persons

Richard Gosse, P.Geo., Vice President Exploration for Trilogy Metals Inc., is a Qualified Person as defined by National Instrument 43-101 – Standard of Disclosure for Mineral Projects and Subpart 1300 of Regulation S-K. Mr. Gosse has reviewed the technical information in this news release and approves the disclosure contained herein.

About
Trilogy Metals

Trilogy Metals Inc. is a metal exploration and development company holding a 50 percent interest in Ambler Metals LLC, which has a 100 percent interest in the Upper Kobuk Mineral Projects in northwestern Alaska. On December 19, 2019, South32, a globally diversified mining and metals company, exercised its option to form a 50/50 joint venture with Trilogy Metals. The UKMP is located within the Ambler Mining District which is one of the richest and most-prospective known copper-dominant districts in the world. It hosts world-class polymetallic volcanogenic massive sulphide (“VMS”) deposits that contain copper, zinc, lead, gold and silver, and carbonate replacement deposits which have been found to host high-grade copper and cobalt mineralization. Exploration efforts have been focused on two deposits in the Ambler Mining District – the Arctic VMS deposit and the Bornite carbonate replacement deposit. Both deposits are located within a land package that spans approximately 190,929 hectares. Ambler Metals has an agreement with NANA Regional Corporation, Inc., an Alaska Native Corporation that provides a framework for the exploration and potential development of the Ambler Mining District in cooperation with local communities. Trilogy Metal’s vision is to develop the Ambler Mining District into a premier North American copper producer while protecting and respecting subsistence livelihoods.


Cautionary Note Regarding Forward-Looking Statements

This press release includes certain “forward-looking information” and “forward-looking statements” (collectively “forward-looking statements”) within the meaning of applicable Canadian and United States securities legislation including the United States Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical fact, included herein, including, without limitation, potential actions and effects resulting from the executive orders and statements from the Department of the Interior, Bureau of Land Management, perceived merit of properties, the sufficiency of cash for the next twelve months and the Company’s plans to provide further updates and the timing thereof are forward-looking statements. Forward-looking statements are frequently, but not always, identified by words such as “expects”, “anticipates”, “believes”, “intends”, “estimates”, “potential”, “possible”, and similar expressions, or statements that events, conditions, or results “will”, “may”, “could”, or “should” occur or be achieved. Forward-looking statements involve various risks and uncertainties. There can be no assurance that such statements will prove to be accurate, and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company’s expectations include the uncertainties involving our assumptions with respect to those uncertainties disclosed in the Company’s Annual Report on Form 10-K for the year ended November 30, 2024 filed with Canadian securities regulatory authorities and with the United States Securities and Exchange Commission and in other Company reports and documents filed with applicable securities regulatory authorities from time to time. The Company’s forward-looking statements reflect the beliefs, opinions and projections on the date the statements are made. The Company assumes no obligation to update the forward-looking statements or beliefs, opinions, projections, or other factors, should they change, except as required by law.

Cision View original content:https://www.prnewswire.com/news-releases/trilogy-metals-reports-first-quarter-fiscal-2025-financial-results-302417690.html

SOURCE Trilogy Metals Inc.

Queue-it Joins Elite Group of Qualified Compute Partners at Akamai

PR Newswire


CAMBRIDGE, Mass.
, April 2, 2025 /PRNewswire/ — Akamai Technologies Inc. (NASDAQ: AKAM), the cybersecurity and cloud computing company that powers and protects business online, announced today that Queue-it is the latest organization to join the Akamai Qualified Compute Partner Program as an Independent Software Vendor (ISV). Queue-it is the leading provider of virtual waiting room services, empowering organizations to control peak traffic and deliver reliable, fair, and transparent online experiences—no matter the demand.

As an ISV in the Akamai Qualified Compute Partner Program, Queue-it’s virtual waiting room technology integrates seamlessly with Akamai’s EdgeWorkers platform to help enterprise organizations manage peak traffic and safeguard critical infrastructure 24/7. The virtual waiting room controls the flow of visitors to web applications, protecting key bottlenecks and stabilizing uptime without costly overprovisioning or complex re-architecting. During traffic surges, site visitors are automatically flowed to an online queue with transparent wait information, fair first-in-first-out or randomized access logic, and robust bot mitigation.

For businesses, this translates into fewer disruptions on critical days, optimized infrastructure costs, and protected sales revenue and brand reputation. The collaboration provides organizations with 24/7 safety net coverage for unexpected traffic spikes and helps them successfully capitalize on peak demand scenarios including product drops, flash sales, and registrations. The virtual waiting room has proved essential for over 1,000 organizations across the ticketing, government, online retail, telecommunications, financial services, and education industries.

“Akamai has been a key strategic partner for Queue-it since we first teamed up to improve digital vaccine registrations through Vaccine Edge in 2021,” says Jesper Essendrop, CEO at Queue-it. “Since then, we’ve been the first partner to go to market with EdgeWorkers, supported over 100 shared customers on their busiest days, and processed over 30 billion visitors through Queue-it’s Akamai Edge Connector. By joining the Qualified Compute Partner Program, we’re expanding our end-to-end support of Akamai customers by enabling them to run Queue-it fully on Akamai Cloud for added security, availability, and resilience. Today’s announcement is a significant leap forward for Akamai customers seeking to deliver fair, reliable, trust-building online experiences for their customers on high-traffic days.”

“Akamai is pleased to make Queue-it’s virtual waiting room easily available to Akamai customers through the Akamai Qualified Compute Partner Program,” said Dan Lawrence, Senior Vice President, Cloud Computing, Akamai. “Enterprises and governments are now able to build online trust, prevent website overload on their business-critical days, and scale it across Akamai Cloud, the world’s most distributed platform for cloud computing, security, and content delivery.”

The Akamai Qualified Compute Partner Program is designed to make solution-based services that are interoperable with Akamai cloud computing services easily accessible to Akamai customers. The services are provided by Akamai technology partners that complete a rigorous qualification process to ensure they are readily available to deploy and scale across the globally distributed Akamai Cloud. The services are available individually or can work together to form a larger ecosystem of complementary capabilities, which can offer performance and cost benefits by running on a single global platform.

To learn more about the Akamai Qualified Compute Partner Program or to join the leading technology companies that partner with Akamai, visit the Akamai Technology Partner Program page.

Additional information about Akamai’s cloud computing services is available at akamai.com.

About Queue-it
Queue-it is the leading developer of virtual waiting room services, empowering 1,000+ organizations worldwide to build and nurture trust with 30+ billion visitors annually by delivering reliable, fair, and transparent online experiences. Queue-it helps some of the world’s biggest governments, retailers, and ticketing companies to capitalize on peak traffic events by preventing website crashes, blocking bots, and mitigating load-induced errors such as overselling. Queue-it is headquartered in Denmark with offices in the U.S., Australia, and the Republic of Korea. For more information, please visit https://queue-it.com.

About Akamai
Akamai is the cybersecurity and cloud computing company that powers and protects business online. Our market-leading security solutions, superior threat intelligence, and global operations team provide defense-in-depth to safeguard enterprise data and applications everywhere. Akamai’s full-stack cloud computing solutions deliver performance and affordability on the world’s most distributed platform. Global enterprises trust Akamai to provide the industry-leading reliability, scale, and expertise they need to grow their business with confidence. Learn more at akamai.com and akamai.com/blog, or follow Akamai Technologies on X and LinkedIn.

Contacts:
Jillian Als
VP of Marketing, Queue-it
+45 31 36 09 50
[email protected]

Akamai Media Relations
[email protected]

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/queue-it-joins-elite-group-of-qualified-compute-partners-at-akamai-302417598.html

SOURCE Akamai Technologies, Inc.

Trimble Adds New API Capabilities to Accubid Anywhere Estimating Application

PR Newswire

Automated connectivity enhances data analysis and collaboration for electrical contractors


WESTMINSTER, Colo.
, April 2, 2025 /PRNewswire/ — Trimble® (Nasdaq: TRMB) today announced the availability of new application programming interfaces (APIs) for Trimble Accubid® Anywhere, a cloud-hosted estimating software for electrical projects. These connection capabilities help electrical contractors better collect, analyze and share data to improve estimating insight and collaboration across the construction lifecycle.

Five Accubid Anywhere APIs provide a comprehensive suite that helps estimators pull bid data into dashboards and reporting for analysis and improvement of estimating efforts:

  • A Project API provides a list of projects with the project details that can be extracted to other software.
  • An Estimate API captures all of the estimate information for users to extract into their ERP, including a list of estimates with their details and bid summaries.
  • A Final Price API allows users to compare initial estimates and final prices for different projects.
  • An Extension API allows users to send bill of materials (BOM) to other software.
  • A Bid Breakdown API enables users to more easily retrieve and analyze data points such as field, shop and incidental labor from closeout screens at a line-item level of detail.

Automated API connectivity from estimating to related systems — including ERP, project management and CRM — also eliminates manual data transfer, allowing contractors to collaborate and work more efficiently across workflows.

With robust estimating functionality, integrated graphical takeoff, change order management, pricing, submittal management, and more, Accubid Anywhere helps electrical estimators bid with speed and accuracy.

The expanding suite of Accubid Anywhere APIs reflects Trimble’s commitment to bringing benefits of data connectivity to contractors using systems from Trimble and from other suppliers within construction technology ecosystems.

“Estimates generate a high volume of valuable data that should be analyzed and used in other workflows, but this data often gets trapped in the estimating system,” said Lawrence Smith, vice president, construction management systems at Trimble. “Using APIs to extract and connect data automatically to other systems means contractors don’t have to import, export or manually re-type the information. This improves efficiency and decision making on both the project and operational level.”

“Accubid Anywhere APIs allow us to see who created projects and estimates, along with where and when they were created for a better understanding of our bids,” said Beau Brenno, director of business Intelligence / artificial Intelligence at Hunt Electric, a national electrical design, build, and maintenance firm based in Minnesota. “We are in the process of connecting those estimates to the jobs they become to compare how we estimated versus how the job was executed. This gives us much greater insight into where the estimate went right, where it went wrong and how we can improve estimates in the future.”

Availability
Trimble Accubid Anywhere APIs are available in North America to customers with an Accubid Anywhere subscription.

More technical information is available on the Developer Documentation website at: https://developer.trimble.com/docs/accubid-anywhere.

For more information on Trimble Accubid Anywhere electrical estimating software, visit:  https://mep.trimble.com/en/electrical-solutions/estimating-and-takeoff/trimble-accubid-anywhere.

About Trimble
Trimble is transforming the ways people move, build and live. Core technologies in positioning, modeling and data analytics connect the digital and physical worlds to improve our customers’ productivity, quality, safety, transparency and sustainability. For more information about Trimble (Nasdaq: TRMB), visit: www.trimble.com.

GTRMB

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/trimble-adds-new-api-capabilities-to-accubid-anywhere-estimating-application-302417688.html

SOURCE Trimble

WYNDHAM HOTELS & RESORTS TO REPORT FIRST QUARTER 2025 EARNINGS ON APRIL 30, 2025

PR Newswire

Will Host Conference Call and Webcast on May 1, 2025 at 8:30 a.m. ET


PARSIPPANY, N.J.
, April 2, 2025 /PRNewswire/ — Wyndham Hotels & Resorts (NYSE: WH) announced today that it will report first quarter 2025 results on Wednesday, April 30, 2025 at approximately 4:30 p.m. ET.  Geoff Ballotti, president and chief executive officer, and Michele Allen, chief financial officer and head of strategy, will host a call with investors on May 1, 2025 at 8:30 a.m. ET to discuss the Company’s results and business outlook.

Listeners can access the webcast live through the Company’s website at https://investor.wyndhamhotels.com.  The conference call may also be accessed by calling 800 343-4136 and providing the passcode “Wyndham.”  Listeners are urged to call at least five minutes prior to the scheduled start time.  An archive of this webcast will be available on the website beginning at noon ET on May 1, 2025.  A telephone replay will be available for approximately ten days beginning at noon ET on May 1, 2025 at 800 688-9459.


About Wyndham Hotels & Resorts

Wyndham Hotels & Resorts (NYSE: WH) is the world’s largest hotel franchising company by the number of franchised properties, with approximately 9,300 hotels across over 95 countries on six continents.  Through its network of approximately 903,000 rooms appealing to the everyday traveler, Wyndham commands a leading presence in the economy and midscale segments of the lodging industry.  The Company operates a portfolio of 25 hotel brands, including Super 8®, Days Inn®, Ramada®, Microtel®, La Quinta®, Baymont®, Wingate®, AmericInn®, ECHO Suites®, Registry Collection Hotels®,Trademark Collection® and Wyndham®. The Company’s award-winning Wyndham Rewards loyalty program offers approximately 114 million enrolled members the opportunity to redeem points at thousands of hotels, vacation club resorts and vacation rentals globally. For more information, visit www.wyndhamhotels.com. The Company may use its website and social media channels as means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD. Disclosures of this nature will be included on the Company’s website in the Investors section, which can currently be accessed at https://investor.wyndhamhotels.com or on the the Company’s social media channels, including the Company’s LinkedIn account which can currently be accessed at https://www.linkedin.com/company/wyndhamhotels. Accordingly, investors should monitor this section of the Company’s website and the Company’s social media channels in addition to following the Company’s press releases, filings submitted with the Securities and Exchange Commission and any public conference calls or webcasts.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/wyndham-hotels–resorts-to-report-first-quarter-2025-earnings-on-april-30-2025-302417195.html

SOURCE Wyndham Hotels & Resorts

Mobileye selects Valens Semiconductor’s VA7000 MIPI A-PHY chipsets for automated and autonomous driving projects

PR Newswire

Optimized optical path collaboration to be used on select production programs based on the Mobileye EyeQ™6 High system-on-chip.

HOD HASHARON, Israel, April 2, 2025 /PRNewswire/ — Valens Semiconductor (NYSE: VLN) (‘Valens’), a leader in high-performance connectivity, announced today that Valens’ VA7000 MIPI A-PHY-compliant chipsets will form the in-car, sensor to compute connectivity infrastructure for Mobileye EyeQ6 High automated and autonomous production programs underway with a group of global automotive brands. This marks a significant milestone for MIPI A-PHY, as the automotive industry continues to coalesce around this global standard for high-speed connectivity.

“We are pleased to utilize Valens’ MIPI A-PHY-compliant VA7000 chipsets as a key component of the optical path that supports automated and autonomous driving platforms for this initial customer program,” said Elchanan Rushinek, executive vice president of engineering at Mobileye. “MIPI A-PHY delivers efficient and robust high-performance standardized connectivity and we look forward to working with Valens to broaden the MIPI A-PHY ecosystem and deliver this technology to more market-leading automakers.”

Mobileye selected the VA7000 for this application following extensive testing of the chipset, where the Valens chip was found superior across a variety of parameters, with significant performance benefits.

“Our collaboration with Mobileye, a market leader in ADAS and autonomous systems, is validation of the promise made by MIPI A-PHY,” said Gideon Ben-Zvi, CEO of Valens Semiconductor. “SoCs can only ever be as good as the sensor data inputs they operate on, and Mobileye’s selection of our VA7000 chipset proves that our solution is well positioned to deliver that data at high accuracy. With a transformative company such as Mobileye validating the performance of the Valens VA7000 A-PHY chip, this collaboration marks a significant milestone for the entire automotive industry.”

MIPI A-PHY is the first automotive industry standard developed for high-speed sensor and display connectivity. It is uniquely designed to meet next-generation ADAS requirements, enabling high-bandwidth, low-latency connectivity and uncompromised passenger safety throughout the entire life cycle of the vehicle. Since its release, the MIPI A-PHY ecosystem continues to grow and diversify, attracting new companies that are designing products based on this connectivity standard. Valens Semiconductor, a key contributor to the standard, was the first on the market to offer A-PHY-compliant products with its VA7000 chipsets.


About Mobileye Global Inc

Mobileye (NASDAQ: MBLY) leads the mobility revolution with our autonomous driving and driver-assistance technologies, harnessing world-renowned expertise in artificial intelligence, computer vision, mapping and integrated software and hardware. Since our founding in 1999, Mobileye has enabled the wide adoption of advanced driver-assistance systems that bolster driving safety, while pioneering such groundbreaking technologies as REM crowdsourced mapping, True Redundancy sensing, and Responsibility Sensitive Safety (RSS). These technologies drive the ADAS and AV fields towards the future of mobility – enabling self-driving vehicles and mobility solutions at scale, and powering industry-leading advanced driver-assistance systems. Through 2024, more than 200 million vehicles worldwide have been built with Mobileye’s EyeQ technology inside. Since 2022, Mobileye has been listed independently from Intel (NASDAQ: INTC), which retains majority ownership. For more information, visit https://www.mobileye.com.


About Valens Semiconductor

Valens Semiconductor (NYSE: VLN) is a leader in high-performance connectivity, enabling customers to transform the digital experiences of people worldwide. Valens’ chipsets are integrated into countless devices from leading customers, powering state-of-the-art audio-video installations, next-generation videoconferencing, and enabling the evolution of ADAS and autonomous driving. Pushing the boundaries of connectivity, Valens sets the standard everywhere it operates, and its technology forms the basis for the leading industry standards such as HDBaseT® and MIPI A-PHY. For more information, visit https://www.valens.com/.


Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “expect,” “anticipate,” “believe,” “seek,” “target” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding the performance and usage of our chipsets. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of Valens Semiconductor’s (“Valens”) management and are not predictions of actual performance. These forward-looking statements are provided for illustrative purposes only and are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, a prediction or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. Many actual events and circumstances are beyond the control of Valens Semiconductor. These forward-looking statements are subject to a number of risks and uncertainties, including the cyclicality of the semiconductor industry; the effect of inflation and a rising interest rate environment on our customers and industry; the ability of our customers to absorb inventory; competition in the semiconductor industry, and the failure to introduce new technologies and products in a timely manner to compete successfully against competitors; if Valens fails to adjust its supply chain volume due to changing market conditions or fails to estimate its customers’ demand; disruptions in relationships with any one of Valens’ key customers; any difficulty selling Valens’ products if customers do not design its products into their product offerings; Valens’ dependence on winning selection processes; even if Valens succeeds in winning selection processes for its products, Valens may not generate timely or sufficient net sales or margins from those wins; sustained yield problems or other delays or quality events in the manufacturing process of products; our ability to effectively manage, invest in, grow, and retain our sales force, research and development capabilities, marketing team and other key personnel; our ability to timely adjust product prices to customers following price increase by the supply chain; our ability to adjust our inventory level due to reduction in demand due to inventory buffers accrued by customers; our expectations regarding the outcome of any future litigation in which we are named as a party; our ability to adequately protect and defend our intellectual property and other proprietary rights; our ability to successfully integrate or otherwise achieve anticipated benefits from acquired businesses; the market price and trading volume of the Valens ordinary shares may be volatile and could decline significantly; political, economic, governmental and tax consequences associated with our incorporation and location in Israel; and those factors discussed in Valens’ Form 20-F filed with the SEC on February 26, 2025 under the heading “Risk Factors,” and other documents of Valens filed, or to be filed, with the SEC. If any of these risks materialize or our assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Valens does not presently know or that Valens currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Valens’ expectations, plans or forecasts of future events and views as of the date of this press release. Valens anticipates that subsequent events and developments may cause Valens’ assessments to change. However, while Valens may elect to update these forward-looking statements at some point in the future, Valens specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Valens’ assessment as of any date subsequent to the date of this press release. Accordingly, undue reliance should not be placed upon the forward-looking statements.

Mobileye Contact

[email protected]

Valens Media Contacts

Yoni Dayan
Head of Communications
Valens Semiconductor Ltd.
[email protected]

Valens Investor Contacts:

Michal Ben Ari

Investor Relations Manager
Valens Semiconductor Ltd.
[email protected]

Logo: https://mma.prnewswire.com/media/2655162/Valens_Mobileye.jpg

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mobileye-selects-valens-semiconductors-va7000-mipi-a-phy-chipsets-for-automated-and-autonomous-driving-projects-302418259.html

SOURCE Valens Semiconductor

Hyperscale Data Announces 56 Bitcoin Mined Year to Date and 3,061 Bitcoin Mined Since Inception of Mining Operations in March 2021

LAS VEGAS, April 02, 2025 (GLOBE NEWSWIRE) — Hyperscale Data, Inc. (NYSE American: GPUS), a diversified holding company (“Hyperscale Data” or the “Company”), today announced that its wholly owned subsidiary Sentinum, Inc. (“Sentinum”) mined approximately 56 Bitcoin from January 1, 2025, to March 31, 2025. Since March of 2021, Sentinum has mined approximately 3,061 Bitcoin.

“The Company is proud of the Sentinum team and the efficiency with which the mining operations are run. We believe it is important to update stockholders on our current and historical Bitcoin mining operations and of Sentinum’s accomplishments in the Bitcoin mining space,” stated William B. Horne, Chief Executive Officer of Hyperscale Data. “The Company has previously noted its intentions to relocate the majority of its Bitcoin mining operations concurrently with the buildout of its Michigan Data Center and will continue to update stockholders as this progresses.”

For more information on Hyperscale Data and its subsidiaries, Hyperscale Data recommends that stockholders, investors and any other interested parties read Hyperscale Data’s public filings and press releases available under the Investor Relations section at hyperscaledata.com or available at www.sec.gov.

About Hyperscale Data, Inc.

Through its wholly owned subsidiaries, Hyperscale Data owns and operates a data center at which it mines digital assets and offers colocation and hosting services for the emerging artificial intelligence ecosystems and other industries. Hyperscale Data’s subsidiary, Ault Capital Group, Inc. (“ACG”), is a diversified holding company pursuing growth by acquiring undervalued businesses and disruptive technologies with a global impact.

Hyperscale Data intends to completely divest itself of ACG on or about December 31, 2025, at which time, it would solely be an owner and operator of data centers to support high-performance computing services. Until that happens, the Company provides, through ACG and its wholly and majority-owned subsidiaries and strategic investments, mission-critical products that support a diverse range of industries, including an artificial intelligence software platform, social gaming platform, equipment rental services, defense/aerospace, industrial, automotive, medical/biopharma and hotel operations. In addition, ACG is actively engaged in private credit and structured finance through a licensed lending subsidiary. Hyperscale Data’s headquarters are located at 11411 Southern Highlands Parkway, Suite 190 Las Vegas, NV 89141.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “believes,” “plans,” “anticipates,” “projects,” “estimates,” “expects,” “intends,” “strategy,” “future,” “opportunity,” “may,” “will,” “should,” “could,” “potential,” or similar expressions. Statements that are not historical facts are forward-looking statements. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties.

Forward-looking statements speak only as of the date they are made, and the Company undertakes no obligation to update any of them publicly in light of new information or future events. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors. More information, including potential risk factors, that could affect the Company’s business and financial results are included in the Company’s filings with the U.S. Securities and Exchange Commission, including, but not limited to, the Company’s Forms 10-K, 10-Q and 8-K. All filings are available at www.sec.govand on the Company’s website at hyperscaledata.com.

Hyperscale Data Investor Contact:


[email protected]
or 1-888-753-2235



Enovis Announces Appointment of Damien McDonald as Chief Executive Officer

  • Damien McDonald appointed CEO, effective as of May 12, 2025
  • Company reiterates guidance for first quarter revenues and aEBITDA

WIlmington. DE, April 02, 2025 (GLOBE NEWSWIRE) — Enovis™ Corporation (“Enovis” or “The Company”) (NYSE: ENOV), a leader in medical technology innovation, today announced the appointment of Damien McDonald as Chief Executive Officer, effective May 12, 2025. Mr. McDonald will also join the Enovis Board of Directors following the conclusion of the Company’s 2025 Annual Meeting of Stockholders on May 21, 2025. He will succeed Matt Trerotola, who previously announced his intention to retire as CEO and has informed the Board that he will not stand for re-election at the Annual Meeting. Enovis also reiterated its expectations for first quarter revenues to be in the range of $555 to $563 million and adjusted EBITDA in the range of $97 to $100 million. 

Sharon Wienbar, Lead Independent Director at Enovis, stated, “On behalf of the Board, I am thrilled to welcome Damien to the Enovis team. The Board of Directors, with the assistance of a leading executive search firm, carefully identified, evaluated and interviewed highly qualified candidates and Damien stood out. His strong track record as CEO of a public, global medical technology combined with his long history of relevant business successes and his similar approach to business processes and culture make him the right leader for Enovis at this stage in our growth journey.”

Mr. McDonald joins Enovis with more than 35 years of experience in the medical device industry. Most recently, he served as CEO of LivaNova, a global business creating clinically differentiated medical devices for the head and heart to improve the lives of patients worldwide. In his six years there, he drove improved results in growth, profitability and shareholder value. He also made a meaningful impact on company culture, centered on a ‘Patients First’ mindset. Earlier in his career, he was a Group Executive and Corporate Vice President leading a $1.5 billion group of dental consumables companies at Danaher. Additionally, he previously led Zimmer’s spine division and global marketing for J&J’s Ethicon business unit.

“I am honored to join the Enovis team at this exciting time in the Company’s history and to have the opportunity to lead the Company into its next phase of growth,” says Mr. McDonald. “I share the Company’s vision of developing innovative technologies to improve patient outcomes and I look forward to building upon Enovis’ strong foundation and delivering exceptional value for all of our stakeholders.”

Mr. Trerotola said, “Damien has the experience, track record, and cultural fit to be a fantastic next leader of Enovis. I am grateful for the opportunity to lead Colfax and Enovis for the past decade and look forward to a smooth transition that continues to build on the Company’s great operational and strategic momentum.”

Enovis also announced that Ms. Wienbar will assume the role of independent Chair of the Board following Mr. Trerotola’s retirement at the Annual Meeting. The Company will take questions regarding the management transition plan on its first quarter 2025 earnings call scheduled for May 8, 2025, at 8:30 a.m. ET.

About Enovis

Enovis Corporation (NYSE: ENOV) is an innovation-driven medical technology growth company dedicated to developing clinically differentiated solutions that generate measurably better patient outcomes and transform workflows. Powered by a culture of continuous improvement, global talent and innovation, the Company’s extensive range of products, services and integrated technologies fuels active lifestyles in orthopedics and beyond. The Company’s shares of common stock are listed in the United States on the New York Stock Exchange under the symbol ENOV. For more information about Enovis, please visit www.enovis.com.

Availability of Information on the Enovis Website

Investors and others should note that Enovis routinely announces material information to investors and the marketplace using SEC filings, press releases, public conference calls, webcasts and the Enovis Investor Relations website. While not all of the information that the Company posts to the Enovis Investor Relations website is of a material nature, some information could be deemed to be material. Accordingly, the Company encourages investors, the media and others interested in Enovis to review the information that it shares on ir.enovis.com.

Forward-Looking Statements

This press release includes forward-looking statements, including forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements concerning Enovis’ plans, goals, objectives, outlook, expectations and intentions, and other statements that are not historical or current fact. Forward-looking statements are based on Enovis’ current expectations and involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such forward-looking statements. Factors that could cause Enovis’ results to differ materially from current expectations include, but are not limited to, risks related to the impact of public health emergencies and global pandemics (including COVID-19); disruptions in the global economy caused by escalating geopolitical tensions including in connection with Russia’s invasion of Ukraine; macroeconomic conditions, including the impact of inflationary pressures; supply chain disruptions; increasing energy costs and availability concerns, particularly in the European market; other impacts on Enovis’ business and ability to execute business continuity plans; and the other factors detailed in Enovis’ reports filed with the U.S. Securities and Exchange Commission (the “SEC”), including its most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q under the caption “Risk Factors,” as well as the other risks discussed in Enovis’ filings with the SEC. In addition, these statements are based on assumptions that are subject to change. This press release speaks only as of the date hereof. Enovis disclaims any duty to update the information herein.

Kyle Rose
Vice President, Investor Relations
Enovis Corporation
[email protected]



AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

AngioDynamics Reports Fiscal Year 2025 Third Quarter Financial Results

LATHAM, N.Y.–(BUSINESS WIRE)–
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options, and improving quality of life for patients, today announced financial results for the third quarter of fiscal year 2025, which ended February 28, 2025.

Fiscal Year 2025 Third Quarter Highlights

 

Quarter Ended

February 28, 2025

Pro Forma* YoY Growth

Pro Forma* Net Sales

$72.0 million

9.2%

Med Tech Net Sales

$31.3 million

22.2%

Med Device Net Sales

$40.7 million

0.9%

  • GAAP gross margin of 54.0%
  • GAAP loss per share of $(0.11)
  • Adjusted loss per share of $(0.08)
  • Adjusted EBITDA of $1.3 million
  • Initiated the AMBITION BTK RCT and Registry to generate definitive clinical evidence supporting the use of the Auryon Atherectomy System in treating below the knee lesions in patients with critical limb ischemia
  • Published APEX-AV trial results in JSCAI demonstrating the safety and efficacy of the AlphaVac F1885 System
  • Received FDA 510(k) clearance for NanoKnife System for prostate tissue ablation
  • Increasing fiscal year 2025 guidance for net sales, Med Tech net sales growth, gross margin, Adjusted EBITDA, and Adjusted EPS

*Pro forma results exclude the Dialysis and BioSentry businesses divested in June 2023 and the PICC and Midline product portfolios divested in February 2024, as well as the discontinued Radiofrequency and Syntrax products in February 2024.

“We are very pleased with our third quarter performance as we continued to drive strong topline growth and adjusted EBITDA profitability. Our ability to deliver consistently strong results comes as a result of the significant transformation we have undergone over the last few years to simplify our business and focus on large, fast-growing MedTech markets,” said Jim Clemmer, President and Chief Executive Officer of AngioDynamics. “To that end, we’re seeing impressive momentum across our MedTech franchise, which grew over 20% for the second quarter in a row, driven by growth within each of our MedTech platform technologies, Auryon, AngioVac, AlphaVac, and NanoKnife. In lock-step with this growth, we continue to improve gross margins and operational efficiency, which allowed us to deliver yet another quarter of positive adjusted EBITDA. Based on the quality of performance we have seen through fiscal 2025, we are increasing our fiscal full year guidance for all of our key metrics, including; total worldwide revenue, MedTech revenue growth, gross margin, adjusted EBITDA, and adjusted EPS.”

“As we look ahead, we are well positioned to deliver profitable growth going forward. With the many catalysts we have recently achieved, including FDA clearance for our NanoKnife System for prostate tissue ablation, our portfolio is the strongest it has been. With our improved operating leverage and strong balance sheet, we can continue to prudently invest to support high impact initiatives while remaining on track to hit our fiscal year 2026 profitability targets,” continued Mr. Clemmer.

Third Quarter 2025 Financial Results

Unless otherwise noted, all financial metrics and growth rates presented below are on a pro forma basis.

Net sales for the third quarter of fiscal year 2025 were $72.0 million, an increase of 9.2% compared to the prior-year quarter.

Med Tech net sales were $31.3 million, a 22.2% increase from $25.7 million in the prior-year period. Med Tech includes the Auryon peripheral atherectomy platform, the thrombus management platform, which includes the AlphaVac and AngioVac mechanical thrombectomy systems, and the NanoKnife irreversible electroporation platform.

Growth in the Med Tech segment for the quarter was driven by strength across all product lines, including Auryon sales of $13.9 million, which increased 17.3%, AngioVac sales of $6.8 million, which increased 23.1%, AlphaVac sales of $3.0 million, which increased 161.4%, and NanoKnife disposable sales of $4.9 million, which increased 16.2%. Total NanoKnife sales, including capital, of $6.3 million, increased 5.3%.

Med Device net sales were $40.7 million, an increase of 0.9% compared to $40.3 million in the prior-year period.

U.S. net sales in the third quarter of fiscal 2025 were $61.3 million, an increase of 9.9% from $55.8 million a year ago. International net sales were $10.7 million, an increase of 5.1%, compared to $10.1 million a year ago.

Gross margin for the third quarter of fiscal 2025 was 54.0%, which was 290 basis points up compared to the third quarter of fiscal 2024.

Gross margin for the Med Tech business was 62.5%, an increase of 100 basis points from the third quarter of fiscal 2024 driven by the growth of AngioVac sales, as well as a higher mix of Auryon hospital-based sales. Gross margin for the Med Device business was 47.4%, an increase of 300 basis points compared to the third quarter of fiscal 2024.

The Company recorded a non-pro forma GAAP net loss of $4.4 million, or a loss per share of $0.11, in the third quarter of fiscal 2025. Excluding the items shown in the non-GAAP reconciliation table below, adjusted net loss for the third quarter of fiscal 2025 was $3.1 million, or a loss per share of $0.08. This compares to an adjusted net loss during the fiscal third quarter of 2024 of $6.5 million, or a loss per share of $0.16.

Adjusted EBITDA in the third quarter of fiscal 2025, excluding the items shown in the non-GAAP reconciliation table below, was $1.3 million, compared to a loss of $3.6 million in the third quarter of fiscal 2024.

In the third quarter of fiscal 2025, the Company utilized $13.2 million in operating cash, and at February 28, 2025, the Company had $44.8 million in cash and cash equivalents compared to $54.1 million in cash and cash equivalents at November 30, 2024. This is in-line with the Company’s stated expectations following its second fiscal quarter. As the Company previously stated, in the fourth quarter of fiscal 2025, the Company expects to generate positive operating cash flow, ending with cash and cash equivalents around $55 million with zero debt. In addition, the Company remains on track to achieve positive operating cash flow for the full year of fiscal 2026.

Subsequent to the end of the third quarter of fiscal 2025, the Company announced that it secured a commitment from J.P. Morgan regarding a revolving line of credit agreement (“the revolver”), which allows the Company to draw down up to $25.0 million at its discretion. While the Company is well capitalized with existing cash on hand, the Company stated that entering into the revolver reflects good financial management and offers incremental flexibility to manage potential working capital fluctuations as part of its manufacturing transfer process without impacting its ability to execute on its strategic growth trajectory moving forward.

Auryon

Initiated AMBITION BTK RCT and Registry to Advance Treatment for Critical Limb Ischemia

The Company initiated the AMBITION BTK (below the knee) randomized controlled trial and registry to evaluate the effectiveness of the Auryon Atherectomy System in treating critical limb ischemia below the knee. The multicenter study will enroll up to 200 subjects across 30 sites for the RCT, plus up to 1,500 subjects in a companion registry, comparing the system in combination with standard balloon angioplasty versus angioplasty alone for below the knee lesions. This study builds on previous clinical success demonstrating the system’s ability to safely treat complex below the knee cases while effectively reducing clot burden.

AlphaVac

Announced Publication of APEX-AV Trial Results in JSCAI

The Company announced the publication of APEX-AV trial results in the Journal of the Society for Cardiovascular Angiography & Interventions, validating the safety, efficacy, and efficiency of the AlphaVac F1885 System for pulmonary embolism treatment. The peer-reviewed study demonstrated a 35.5% reduction in clot burden, comparing favorably to other mechanical aspiration devices, with notable improvements in both RV/LV ratio and pulmonary artery pressures. The FDA-cleared device features a unique funnel tip design, optional wireless navigation, and blood loss mitigation, addressing a condition that affects approximately 900,000 individuals annually in the United States.

NanoKnife

Received FDA Clearance for The NanoKnife® System for Prostate Tissue Ablation

The Company received FDA 510(k) clearance for the NanoKnife System for prostate tissue ablation following the successful completion of the pivotal PRESERVE clinical study. The trial, which enrolled 121 patients across 17 clinical sites, met its primary effectiveness endpoint with 84% of men free from in-field, clinically significant disease at 12 months post-procedure, while preserving urinary continence in 95.4% of patients and maintaining erectile function sufficient for intercourse in 71.7% of patients. The NanoKnife System is the first and only non-thermal, radiation-free ablation technology for prostate treatment utilizing Irreversible Electroporation technology.

On January 8, 2025, the Company hosted a Virtual NanoKnife Investor Event, which provided insights into the NanoKnife System’s proprietary irreversible electroporation (IRE) technology and how it is poised to become the standard, function-preserving treatment for men with prostate tumors.

To access a replay of the event, visit HERE.

Fiscal Year 2025 Financial Guidance

For fiscal year 2025:

  • The Company now expects net sales to be in the range of $285 to $288 million, up from previously issued guidance of $282 to $288 million, representing growth between 5.3% to 6.4% over fiscal 2024 pro forma revenue of $270.7 million

  • The Company now expects Med Tech net sales to grow in the range of 14% to 16%, an increase from prior guidance of 12% to 15%

  • The Company continues to expect Med Device net sales to be flat

  • The Company now expects Gross Margin to be approximately 53% to 54%, an increase from prior guidance of 52% to 53%

  • The Company now expects Adjusted EBITDA to be in the range of $4.0 to $5.0 million, an increase from prior guidance of $1.0 to $3.0 million, and compared to a pro forma Adjusted EBITDA loss of $3.2 million in fiscal 2024

  • The Company now expects Adjusted loss per share in the range of $0.31 to $0.34, an improvement from prior guidance of a loss of $0.34 to $0.38. This updated guidance compares to a pro forma Adjusted loss per share of $0.45 in fiscal 2024

Guidance Metric

Guidance Action

Current Guidance

(As of Apr. 2, 2025)

Previous Guidance

(Issued on Jan. 8, 2025)

Net Sales

Increased

$285 – $288 million

$282 – $288 million

Med Tech Net Sales Growth

Increased

14 – 16%

12 – 15%

Med Device Net Sales Growth

Unchanged

Flat (unchanged)

Flat

Gross Margin

Increased

53 – 54%

52 – 53%

Adjusted EBITDA

Increased

$4.0 – $5.0 million

$1.0 – $3.0 million

Adjusted EPS

Increased

($0.31) – ($0.34)

($0.34) – ($0.38)

Conference Call

The Company’s management will host a conference call at 8:00 a.m. ET the same day to discuss the results. To participate in the conference call, dial 1-877-407-0784 (domestic) or +1-201-689-8560 (international).

This conference call will also be webcast and can be accessed from the “Investors” section of the AngioDynamics website at www.angiodynamics.com. The webcast replay of the call will be available at the same site approximately one hour after the end of the call.

A recording of the call will also be available, until Wednesday, April 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921 (domestic) or +1-412-317-6671 (international) and enter the passcode 13752371.

Virtual Cardiovascular Investor Event

AngioDynamics will host a virtual cardiovascular investor event immediately following the Company’s Fiscal 2025 Third Quarter Financial Results Conference Call which will start at 9:00am ET. The Company will provide investors a deeper dive into the cardiovascular technology portfolio and strategic vision.

Webcast Registration Link: https://viavid.webcasts.com/starthere.jsp?ei=1712212&tp_key=cedf6b19b1

Use of Non-GAAP Measures

Management uses non-GAAP measures to establish operational goals and believes that non-GAAP measures may assist investors in analyzing the underlying trends in AngioDynamics’ business over time. Investors should consider these non-GAAP measures in addition to, not as a substitute for or as superior to, financial reporting measures prepared in accordance with GAAP. In this news release, AngioDynamics has reported pro forma results, adjusted EBITDA, adjusted net income and adjusted earnings per share. Management uses these measures in its internal analysis and review of operational performance. Management believes that these measures provide investors with useful information in comparing AngioDynamics’ performance over different periods. By using these non-GAAP measures, management believes that investors get a better picture of the performance of AngioDynamics’ underlying business. Management encourages investors to review AngioDynamics’ financial results prepared in accordance with GAAP to understand AngioDynamics’ performance taking into account all relevant factors, including those that may only occur from time to time but have a material impact on AngioDynamics’ financial results. Please see the tables that follow for a reconciliation of non-GAAP measures to measures prepared in accordance with GAAP.

About AngioDynamics, Inc.

AngioDynamics is a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients.

The Company’s innovative technologies and devices are chosen by talented physicians in fast-growing healthcare markets to treat unmet patient needs. For more information, visit www.angiodynamics.com.

Safe Harbor

This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements regarding AngioDynamics’ expected future financial position, results of operations, cash flows, business strategy, budgets, projected costs, capital expenditures, products, competitive positions, growth opportunities, plans and objectives of management for future operations, as well as statements that include the words such as “expects,” “reaffirms,” “intends,” “anticipates,” “plans,” “believes,” “seeks,” “estimates,” “projects,” “optimistic,” or variations of such words and similar expressions, are forward-looking statements. These forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties. Investors are cautioned that actual events or results may differ materially from AngioDynamics’ expectations, expressed or implied. Factors that may affect the actual results achieved by AngioDynamics include, without limitation, the scale and scope of the COVID-19 global pandemic, the ability of AngioDynamics to develop its existing and new products, technological advances and patents attained by competitors, infringement of AngioDynamics’ technology or assertions that AngioDynamics’ technology infringes the technology of third parties, the ability of AngioDynamics to effectively compete against competitors that have substantially greater resources, future actions by the FDA or other regulatory agencies, domestic and foreign health care reforms and government regulations, results of pending or future clinical trials, overall economic conditions (including inflation, labor shortages and supply chain challenges including the cost and availability of raw materials), the results of on-going litigation, challenges with respect to third-party distributors or joint venture partners or collaborators, the results of sales efforts, the effects of product recalls and product liability claims, changes in key personnel, the ability of AngioDynamics to execute on strategic initiatives, the effects of economic, credit and capital market conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, the ability of AngioDynamics to obtain regulatory clearances or approval of its products, or to integrate acquired businesses, as well as the risk factors listed from time to time in AngioDynamics’ SEC filings, including but not limited to its Annual Report on Form 10-K for the year ended May 31, 2024. AngioDynamics does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

1https://www.wcrf.org/cancer-trends/prostate-cancer-statistics/

 

2 Cheng JY. The Prostate Cancer Intervention Versus Observation Trial (PIVOT) in Perspective. J Clin Med Res. 2013;5(4):266-268. doi:10.4021/jocmr1395w

 

3 Data on file.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

 

 

Three Months Ended

 

Three Months Ended

 

Actual (1)

 

Pro Forma

Adjustments (2)

 

Pro Forma

 

As Reported (1)

 

Pro Forma

Adjustments (2)

 

Pro Forma

 

Feb 28, 2025

 

Feb 28, 2025

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 29, 2024

 

Feb 29, 2024

 

 

 

(unaudited)

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

72,004

 

 

 

9

 

 

$

72,013

 

 

$

75,182

 

 

 

(9,211

)

 

$

65,971

 

Cost of sales (exclusive of intangible amortization)

 

33,147

 

 

 

6

 

 

 

33,153

 

 

 

39,321

 

 

 

(7,038

)

 

 

32,283

 

Gross profit

 

38,857

 

 

 

3

 

 

 

38,860

 

 

 

35,861

 

 

 

(2,173

)

 

 

33,688

 

% of net sales

 

54.0

%

 

 

 

 

54.0

%

 

 

47.7

%

 

 

 

 

51.1

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

6,913

 

 

 

 

 

 

6,913

 

 

 

8,189

 

 

 

(117

)

 

 

8,072

 

Sales and marketing

 

25,504

 

 

 

 

 

 

25,504

 

 

 

25,405

 

 

 

(1,758

)

 

 

23,647

 

General and administrative

 

10,490

 

 

 

 

 

 

10,490

 

 

 

10,578

 

 

 

22

 

 

 

10,600

 

Amortization of intangibles

 

2,598

 

 

 

 

 

 

2,598

 

 

 

3,287

 

 

 

(643

)

 

 

2,644

 

Goodwill impairment

 

 

 

 

 

 

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Change in fair value of contingent consideration

 

40

 

 

 

 

 

 

40

 

 

 

112

 

 

 

 

 

 

112

 

Acquisition, restructuring and other items, net

 

3,286

 

 

 

(3

)

 

 

3,283

 

 

 

35,367

 

 

 

(6,266

)

 

 

29,101

 

Total operating expenses

 

48,831

 

 

 

(3

)

 

 

48,828

 

 

 

242,414

 

 

 

(8,762

)

 

 

233,652

 

Gain on sale of assets

 

 

 

 

 

 

 

 

 

 

6,657

 

 

 

(6,657

)

 

 

 

Operating loss

 

(9,974

)

 

 

6

 

 

 

(9,968

)

 

 

(199,896

)

 

 

(68

)

 

 

(199,964

)

Interest income, net

 

135

 

 

 

 

 

 

135

 

 

 

394

 

 

 

 

 

 

394

 

Other income (expense), net

 

5,430

 

 

 

(5,500

)

 

 

(70

)

 

 

(238

)

 

 

 

 

 

(238

)

Total other income, net

 

5,565

 

 

 

(5,500

)

 

 

65

 

 

 

156

 

 

 

 

 

 

156

 

Loss before income tax benefit

 

(4,409

)

 

 

(5,494

)

 

 

(9,903

)

 

 

(199,740

)

 

 

(68

)

 

 

(199,808

)

Income tax expense (benefit)

 

(2

)

 

 

 

 

 

(2

)

 

 

(12,004

)

 

 

 

 

 

(12,004

)

Net loss

$

(4,407

)

 

$

(5,494

)

 

$

(9,901

)

 

$

(187,736

)

 

$

(68

)

 

$

(187,804

)

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.11

)

 

 

 

$

(0.24

)

 

$

(4.67

)

 

 

 

$

(4.67

)

Diluted

$

(0.11

)

 

 

 

$

(0.24

)

 

$

(4.67

)

 

 

 

$

(4.67

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

Basic

 

40,853

 

 

 

 

 

40,853

 

 

 

40,234

 

 

 

 

 

40,234

 

Diluted

 

40,853

 

 

 

 

 

40,853

 

 

 

40,234

 

 

 

 

 

40,234

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024.

 

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

 

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED INCOME STATEMENTS

(in thousands, except per share data)

 

 

Nine Months Ended

 

Nine Months Ended

 

Actual (1)

 

Pro Forma

Adjustments (2)

 

Pro Forma

 

As Reported (1)

 

Pro Forma

Adjustments (2)

 

Pro Forma

 

Feb 28, 2025

 

Feb 28, 2025

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 29, 2024

 

Feb 29, 2024

 

 

 

(unaudited)

 

 

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net sales

$

212,340

 

 

 

188

 

 

$

212,528

 

 

$

232,934

 

 

 

(33,336

)

 

$

199,598

 

Cost of sales (exclusive of intangible amortization)

 

96,853

 

 

 

155

 

 

 

97,008

 

 

 

116,751

 

 

 

(24,121

)

 

 

92,630

 

Gross profit

 

115,487

 

 

 

33

 

 

 

115,520

 

 

 

116,183

 

 

 

(9,215

)

 

 

106,968

 

% of net sales

 

54.4

%

 

 

 

 

54.4

%

 

 

49.9

%

 

 

 

 

53.6

%

 

 

 

 

 

 

 

 

 

 

 

 

Operating expenses

 

 

 

 

 

 

 

 

 

 

 

Research and development

 

19,632

 

 

 

 

 

 

19,632

 

 

 

24,788

 

 

 

(647

)

 

 

24,141

 

Sales and marketing

 

76,698

 

 

 

 

 

 

76,698

 

 

 

78,237

 

 

 

(4,714

)

 

 

73,523

 

General and administrative

 

31,856

 

 

 

 

 

 

31,856

 

 

 

30,723

 

 

 

(52

)

 

 

30,671

 

Amortization of intangibles

 

7,730

 

 

 

 

 

 

7,730

 

 

 

10,474

 

 

 

(2,571

)

 

 

7,903

 

Goodwill impairment

 

 

 

 

 

 

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Change in fair value of contingent consideration

 

272

 

 

 

 

 

 

272

 

 

 

203

 

 

 

 

 

 

203

 

Acquisition, restructuring and other items, net

 

13,465

 

 

 

161

 

 

 

13,626

 

 

 

44,767

 

 

 

(6,394

)

 

 

38,373

 

Total operating expenses

 

149,653

 

 

 

161

 

 

 

149,814

 

 

 

348,668

 

 

 

(14,378

)

 

 

334,290

 

Gain on sale of assets

 

 

 

 

 

 

 

 

 

 

54,499

 

 

 

(54,499

)

 

 

 

Operating loss

 

(34,166

)

 

 

(128

)

 

 

(34,294

)

 

 

(177,986

)

 

 

(49,336

)

 

 

(227,322

)

Interest income, net

 

975

 

 

 

 

 

 

975

 

 

 

1,047

 

 

 

 

 

 

1,047

 

Other income (expense), net

 

5,269

 

 

 

(5,500

)

 

 

(231

)

 

 

(558

)

 

 

 

 

 

(558

)

Total other income, net

 

6,244

 

 

 

(5,500

)

 

 

744

 

 

 

489

 

 

 

 

 

 

489

 

Loss before income tax benefit

 

(27,922

)

 

 

(5,628

)

 

 

(33,550

)

 

 

(177,497

)

 

 

(49,336

)

 

 

(226,833

)

Income tax expense (benefit)

 

21

 

 

 

 

 

 

21

 

 

 

(6,597

)

 

 

 

 

 

(6,597

)

Net loss

$

(27,943

)

 

$

(5,628

)

 

$

(33,571

)

 

$

(170,900

)

 

$

(49,336

)

 

$

(220,236

)

 

 

 

 

 

 

 

 

 

 

 

 

Loss per share

 

 

 

 

 

 

 

 

 

 

 

Basic

$

(0.68

)

 

 

 

$

(0.82

)

 

$

(4.26

)

 

 

 

$

(5.49

)

Diluted

$

(0.68

)

 

 

 

$

(0.82

)

 

$

(4.26

)

 

 

 

$

(5.49

)

 

 

 

 

 

 

 

 

 

 

 

 

Weighted average shares outstanding

 

 

 

 

 

 

 

 

 

 

 

Basic

 

40,809

 

 

 

 

 

40,809

 

 

 

40,098

 

 

 

 

 

40,098

 

Diluted

 

40,809

 

 

 

 

 

40,809

 

 

 

40,098

 

 

 

 

 

40,098

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the nine months ended February 28, 2025 and February 29, 2024.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

 

Reconciliation of Net Loss to non-GAAP Adjusted Net Income (Loss):

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(4,407

)

 

$

(187,736

)

 

$

(27,943

)

 

$

(170,900

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

2,598

 

 

 

3,287

 

 

 

7,730

 

 

 

10,474

 

Change in fair value of contingent consideration

 

40

 

 

 

112

 

 

 

272

 

 

 

203

 

Acquisition, restructuring and other items, net (1)

 

3,286

 

 

 

35,367

 

 

 

13,465

 

 

 

44,767

 

Goodwill impairment

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Gain on sale of assets

 

 

 

 

(6,657

)

 

 

 

 

 

(54,499

)

Tax effect of non-GAAP items (2)

 

(350

)

 

 

(10,128

)

 

 

1,506

 

 

 

(2,670

)

Adjusted net income (loss)

$

1,167

 

 

$

(6,279

)

 

$

(4,970

)

 

$

(13,149

)

 

 

 

 

 

 

 

 

Reconciliation of Diluted Loss Per Share to non-GAAP Adjusted Diluted Income (Loss) Per Share:

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Diluted loss per share

$

(0.11

)

 

$

(4.67

)

 

$

(0.68

)

 

$

(4.26

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.06

 

 

 

0.08

 

 

 

0.19

 

 

 

0.26

 

Change in fair value of contingent consideration

 

0.01

 

 

 

0.00

 

 

 

0.01

 

 

 

0.01

 

Acquisition, restructuring and other items, net (1)

 

0.08

 

 

 

0.89

 

 

 

0.32

 

 

 

1.11

 

Goodwill impairment

 

 

 

 

3.96

 

 

 

 

 

 

3.98

 

Gain on sale of assets

 

 

 

 

(0.17

)

 

 

 

 

 

(1.36

)

Tax effect of non-GAAP items (2)

 

(0.01

)

 

 

(0.25

)

 

 

0.04

 

 

 

(0.07

)

Adjusted diluted income (loss) per share

$

0.03

 

 

$

(0.16

)

 

$

(0.12

)

 

$

(0.33

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

42,091

 

 

 

40,234

 

 

 

40,809

 

 

 

40,098

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company’s U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2025 and February 29, 2024.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands, except per share data)

 

Reconciliation of Net Loss to Adjusted EBITDA:

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Net loss

$

(4,407

)

 

$

(187,736

)

 

$

(27,943

)

 

$

(170,900

)

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

(2

)

 

 

(12,004

)

 

 

21

 

 

 

(6,597

)

Interest income, net

 

(135

)

 

 

(394

)

 

 

(975

)

 

 

(1,047

)

Depreciation and amortization

 

6,319

 

 

 

7,522

 

 

 

19,967

 

 

 

20,895

 

Goodwill impairment

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Change in fair value of contingent consideration

 

40

 

 

 

112

 

 

 

272

 

 

 

203

 

Stock based compensation

 

2,398

 

 

 

2,612

 

 

 

8,131

 

 

 

8,633

 

Acquisition, restructuring and other items, net (1)

 

2,623

 

 

 

34,232

 

 

 

10,239

 

 

 

43,632

 

Gain on sale of assets

 

 

 

 

(6,657

)

 

 

 

 

 

(54,499

)

Adjusted EBITDA

$

6,836

 

 

$

(2,837

)

 

$

9,712

 

 

$

(204

)

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION

(in thousands, except per share data)

 

Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted Net Loss:

 

 

 

 

 

Pro Forma

 

Pro Forma

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Pro forma net loss

$

(9,901

)

 

$

(187,804

)

 

$

(33,571

)

 

$

(220,236

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

2,598

 

 

 

2,644

 

 

 

7,730

 

 

 

7,903

 

Change in fair value of contingent consideration

 

40

 

 

 

112

 

 

 

272

 

 

 

203

 

Acquisition, restructuring and other items, net (1)

 

3,283

 

 

 

29,101

 

 

 

13,626

 

 

 

38,373

 

Goodwill impairment

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Tax effect of non-GAAP items (2)

 

914

 

 

 

(10,055

)

 

 

2,763

 

 

 

(1,795

)

Adjusted pro forma net loss

$

(3,066

)

 

$

(6,526

)

 

$

(9,180

)

 

$

(16,076

)

 

 

 

 

 

 

 

 

Reconciliation of Pro Forma Diluted Loss Per Share to Pro Forma Adjusted Diluted Loss Per Share:

 

Pro Forma

 

Pro Forma

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Pro forma diluted loss per share

$

(0.24

)

 

$

(4.67

)

 

$

(0.82

)

 

$

(5.49

)

 

 

 

 

 

 

 

 

Amortization of intangibles

 

0.06

 

 

 

0.07

 

 

 

0.19

 

 

 

0.20

 

Change in fair value of contingent consideration

 

0.01

 

 

 

0.01

 

 

 

0.01

 

 

 

0.01

 

Acquisition, restructuring and other items, net (1)

 

0.07

 

 

 

0.72

 

 

 

0.33

 

 

 

0.94

 

Goodwill impairment

 

 

 

 

3.96

 

 

 

 

 

 

3.98

 

Tax effect of non-GAAP items (2)

 

0.02

 

 

 

(0.25

)

 

 

0.07

 

 

 

(0.04

)

Adjusted pro forma diluted loss per share

$

(0.08

)

 

$

(0.16

)

 

$

(0.22

)

 

$

(0.40

)

 

 

 

 

 

 

 

 

Adjusted diluted sharecount (3)

 

40,853

 

 

 

40,234

 

 

 

40,809

 

 

 

40,098

 

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

(2) Adjustment to reflect the income tax provision on a non-GAAP basis has been calculated assuming no valuation allowance on the Company’s U.S. deferred tax assets and an effective tax rate of 23% for the periods ended February 28, 2025 and February 29, 2024.

(3) Diluted shares may differ for non-GAAP measures as compared to GAAP due to a GAAP loss.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

GAAP TO NON-GAAP RECONCILIATION (Continued)

(in thousands, except per share data)

 

Reconciliation of Pro Forma Net Loss to Pro Forma Adjusted EBITDA:

 

 

 

 

 

 

 

Pro Forma

 

Pro Forma

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

 

 

 

 

 

 

 

 

Pro forma net loss

$

(9,901

)

 

$

(187,804

)

 

$

(33,571

)

 

$

(220,236

)

 

 

 

 

 

 

 

 

Income tax expense (benefit)

 

(2

)

 

 

(12,004

)

 

 

21

 

 

 

(6,597

)

Interest income, net

 

(135

)

 

 

(394

)

 

 

(975

)

 

 

(1,047

)

Depreciation and amortization

 

6,319

 

 

 

6,861

 

 

 

19,967

 

 

 

18,234

 

Goodwill impairment

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Change in fair value of contingent consideration

 

40

 

 

 

112

 

 

 

272

 

 

 

203

 

Stock based compensation

 

2,398

 

 

 

2,142

 

 

 

8,131

 

 

 

8,000

 

Acquisition, restructuring and other items, net (1)

 

2,620

 

 

 

27,966

 

 

 

10,400

 

 

 

37,238

 

Adjusted EBITDA

$

1,339

 

 

$

(3,645

)

 

$

4,245

 

 

$

(4,729

)

(1) Includes costs related to merger and acquisition activities, restructuring, and unusual items, including asset impairments and write-offs, certain litigation, and other items.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

ACQUISITION, RESTRUCTURING, AND OTHER ITEMS, NET DETAIL

(in thousands)

 

 

Three Months Ended

 

Nine Months Ended

(in thousands)

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

Legal (1)

$

 

 

$

23,314

 

 

$

406

 

 

$

30,453

 

Mergers and acquisitions

 

 

 

 

147

 

 

 

737

 

 

 

399

 

Plant closure (2)

 

3,130

 

 

 

5,426

 

 

 

11,820

 

 

 

6,115

 

Intangible and other asset impairment

 

 

 

 

6,260

 

 

 

 

 

 

6,260

 

Transition service agreement (3)

 

(463

)

 

 

(333

)

 

 

(1,424

)

 

 

(655

)

Manufacturing relocation (4)

 

 

 

 

 

 

 

 

 

 

587

 

Other (5)

 

619

 

 

 

553

 

 

 

1,926

 

 

 

1,608

 

Total

$

3,286

 

 

$

35,367

 

 

$

13,465

 

 

$

44,767

 

(1) Legal expenses related to litigation that is outside the normal course of business. For the three and nine months ended February 29, 2024, a $19.3 million settlement expense was recorded as a result of the Settlement Agreement that was entered into between the Company and BD.

 

(2) Plant closure expenses, related to the restructuring of our manufacturing footprint which was announced on January 5, 2024.

 

(3) Transition services agreements that were entered into with Merit and Spectrum.

 

(4) Expenses to relocate certain manufacturing lines out of Queensbury, NY.

 

(5) Included in the $1.6 million in other for the nine months ended February 29, 2024 is $0.9 million of deferred financing fees that were written-off in conjunction with the sale of the Dialysis and BioSentry businesses and concurrent extinguishment of the debt.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

 

 

Three Months Ended

 

Three Months Ended

 

 

 

 

 

 

 

 

 

Actual (1)

Pro Forma

Adj. (2)

Pro

Forma

 

As

Reported (1)

Pro Forma

Adj. (2)

Pro

Forma

 

Actual

 

Pro

Forma

 

Feb 28,

2025

Feb 28,

2025

Feb 28,

2025

 

Feb 29,

2024

Feb 29,

2024

Feb 29,

2024

 

%

Growth

Currency

Impact

Constant

Currency

Growth

 

%

Growth

Currency

Impact

Constant

Currency

Growth

 

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Tech

$

31,341

$

$

31,341

 

$

25,844

$

(190

)

$

25,654

 

21.3

%

 

 

 

22.2

%

 

 

Med Device

 

40,663

 

9

 

40,672

 

 

49,338

 

(9,021

)

 

40,317

 

(17.6

)%

 

 

 

0.9

%

 

 

 

$

72,004

$

9

$

72,013

 

$

75,182

$

(9,211

)

$

65,971

 

(4.2

)%

0.2

%

(4.0

)%

 

9.2

%

0.2

%

9.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

61,340

$

4

$

61,344

 

$

62,342

$

(6,521

)

$

55,821

 

(1.6

)%

 

 

 

9.9

%

 

 

International

 

10,664

 

5

 

10,669

 

 

12,840

 

(2,690

)

 

10,150

 

(16.9

)%

1.1

%

(15.8

)%

 

5.1

%

 

 

 

$

72,004

$

9

$

72,013

 

$

75,182

$

(9,211

)

$

65,971

 

(4.2

)%

0.2

%

(4.0

)%

 

9.2

%

0.2

%

9.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

GROSS PROFIT BY PRODUCT CATEGORY

 

 

 

 

 

 

 

 

(in thousands)

 

 

Three Months Ended

 

Three Months Ended

 

 

 

 

 

Actual (1)

Pro Forma

Adj. (2)

Pro

Forma

 

As Reported (1)

Pro Forma

Adj. (2)

Pro

Forma

 

Actual

 

Pro

Forma

 

Feb 28,

2025

Feb 28,

2025

Feb 28,

2025

 

Feb 29,

2024

Feb 29,

2024

Feb 29,

2024

 

% Change

 

% Change

 

(unaudited)

 

(unaudited)

 

 

 

 

Med Tech

$

19,588

 

$

$

19,588

 

 

$

15,857

 

$

(83

)

$

15,774

 

 

23.5

%

 

24.2

%

Gross profit % of sales

 

62.5

%

 

 

62.5

%

 

 

61.4

%

 

 

61.5

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Device

$

19,269

 

$

3

$

19,272

 

 

$

20,004

 

$

(2,090

)

$

17,914

 

 

(3.7

)%

 

7.6

%

Gross profit % of sales

 

47.4

%

 

 

47.4

%

 

 

40.5

%

 

 

44.4

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

38,857

 

$

3

$

38,860

 

 

$

35,861

 

$

(2,173

)

$

33,688

 

 

8.4

%

 

15.4

%

Gross profit % of sales

 

54.0

%

 

 

54.0

%

 

 

47.7

%

 

 

51.1

%

 

 

 

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the three months ended February 28, 2025 and February 29, 2024.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

NET SALES BY PRODUCT CATEGORY AND BY GEOGRAPHY

(in thousands)

 

 

Nine Months Ended

 

Nine Months Ended

 

 

 

 

 

 

 

 

 

Actual (1)

Pro Forma

Adj. (2)

Pro

Forma

 

As

Reported (1)

Pro Forma

Adj. (2)

Pro

Forma

 

Actual

 

Pro

Forma

 

Feb 28,

2025

Feb 28,

2025

Feb 28,

2025

 

Feb 29,

2024

Feb 29,

2024

Feb 29,

2024

 

%

Growth

Currency

Impact

Constant

Currency

Growth

 

%

Growth

Currency

Impact

Constant

Currency

Growth

 

 

(unaudited)

 

 

 

(unaudited)

 

 

 

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Tech

$

90,863

$

$

90,863

 

$

77,068

$

(443

)

$

76,625

 

17.9

%

 

 

 

18.6

%

 

 

Med Device

 

121,477

 

188

 

121,665

 

 

155,866

 

(32,893

)

 

122,973

 

(22.1

)%

 

 

 

(1.1

)%

 

 

 

$

212,340

$

188

$

212,528

 

$

232,934

$

(33,336

)

$

199,598

 

(8.8

)%

0.0

%

(8.8

)%

 

6.5

%

0.1

%

6.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Net Sales

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

United States

$

183,499

$

14

$

183,513

 

$

190,743

$

(23,098

)

$

167,645

 

(3.8

)%

 

 

 

9.5

%

 

 

International

 

28,841

 

174

 

29,015

 

 

42,191

 

(10,238

)

 

31,953

 

(31.6

)%

0.4

%

(31.2

)%

 

(9.2

)%

 

 

 

$

212,340

$

188

$

212,528

 

$

232,934

$

(33,336

)

$

199,598

 

(8.8

)%

0.0

%

(8.8

)%

 

6.5

%

0.1

%

6.6

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the nine months ended February 28, 2025 and February 29, 2024.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

GROSS PROFIT BY PRODUCT CATEGORY

 

 

 

 

 

 

 

 

(in thousands)

 

 

Nine Months Ended

 

Nine Months Ended

 

 

 

 

 

Actual (1)

Pro Forma

Adj. (2)

Pro

Forma

 

As Reported (1)

Pro Forma

Adj. (2)

Pro

Forma

 

Actual

 

Pro

Forma

 

Feb 28,

2025

Feb 28,

2025

Feb 28,

2025

 

Feb 29,

2024

Feb 29,

2024

Feb 29,

2024

 

% Change

 

% Change

 

(unaudited)

 

(unaudited)

 

 

 

 

Med Tech

$

57,398

 

$

$

57,398

 

 

$

48,400

 

$

(155

)

$

48,245

 

 

18.6

%

 

19.0

%

Gross profit % of sales

 

63.2

%

 

 

63.2

%

 

 

62.8

%

 

 

63.0

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Med Device

$

58,089

 

 

33

$

58,122

 

 

$

67,783

 

$

(9,060

)

$

58,723

 

 

(14.3

)%

 

(1.0

)%

Gross profit % of sales

 

47.8

%

 

 

47.8

%

 

 

43.5

%

 

 

47.7

%

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Total

$

115,487

 

$

33

$

115,520

 

 

$

116,183

 

$

(9,215

)

$

106,968

 

 

(0.6

)%

 

8.0

%

Gross profit % of sales

 

54.4

%

 

 

54.4

%

 

 

49.9

%

 

 

53.6

%

 

 

 

 

(1) Reflects the Company’s US GAAP consolidated financial statements before pro forma adjustments related to the sale of the Dialysis and BioSentry Businesses on June 8, 2023, the sale of the PICCs and Midlines Businesses on February 15, 2024 and the discontinuation of the RadioFrequency Ablation and Syntrax products (“the Businesses”) as of February 29, 2024, for the nine months ended February 28, 2025 and 2024.

(2) Reflects the elimination of revenues and expenses representing the operating results from the sales and discontinuation of the Businesses.

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(in thousands)

 

 

Feb 28, 2025

 

May 31, 2024

 

(unaudited)

 

(audited)

Assets

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

44,760

 

$

76,056

Accounts receivable, net

 

43,468

 

 

43,610

Inventories

 

63,105

 

 

60,616

Earn-out receivable

 

5,500

 

 

Prepaid expenses and other

 

15,440

 

 

12,971

Total current assets

 

172,273

 

 

193,253

Property, plant and equipment, net

 

32,530

 

 

35,666

Other assets

 

9,681

 

 

11,369

Intangible assets, net

 

70,931

 

 

77,383

Total assets

$

285,415

 

$

317,671

Liabilities and stockholders’ equity

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

30,265

 

$

37,751

Accrued liabilities

 

36,949

 

 

41,098

Current portion of contingent consideration

 

5,000

 

 

4,728

Other current liabilities

 

5,757

 

 

7,578

Total current liabilities

 

77,971

 

 

91,155

Deferred income taxes

 

4,203

 

 

4,852

Other long-term liabilities

 

17,371

 

 

16,078

Total liabilities

 

99,545

 

 

112,085

Stockholders’ equity

 

185,870

 

 

205,586

Total Liabilities and Stockholders’ Equity

$

285,415

 

$

317,671

ANGIODYNAMICS, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

 

 

Three Months Ended

 

Nine Months Ended

 

Feb 28, 2025

 

Feb 29, 2024

 

Feb 28, 2025

 

Feb 29, 2024

 

(unaudited)

 

(unaudited)

Cash flows from operating activities:

 

 

 

 

 

 

 

Net loss

$

(4,407

)

 

$

(187,736

)

 

$

(27,943

)

 

$

(170,900

)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

 

 

 

 

 

Depreciation and amortization

 

6,319

 

 

 

7,522

 

 

 

19,967

 

 

 

20,895

 

Non-cash lease expense

 

503

 

 

 

484

 

 

 

1,496

 

 

 

1,441

 

Stock based compensation

 

2,398

 

 

 

2,612

 

 

 

8,131

 

 

 

8,633

 

Gain on disposal of assets

 

 

 

 

(6,657

)

 

 

 

 

 

(54,499

)

Transaction costs for disposition

 

 

 

 

(2,657

)

 

 

 

 

 

(5,084

)

Change in fair value of contingent consideration

 

40

 

 

 

112

 

 

 

272

 

 

 

203

 

Impairment loss on indefinite-lived intangible assets (1)

 

 

 

 

159,476

 

 

 

 

 

 

159,476

 

Deferred income taxes

 

(207

)

 

 

(12,094

)

 

 

(795

)

 

 

(7,143

)

Change in accounts receivable allowances

 

142

 

 

 

458

 

 

 

530

 

 

 

1,007

 

Fixed and intangible asset impairments and disposals

 

38

 

 

 

6,845

 

 

 

97

 

 

 

7,084

 

Write-off of other assets

 

 

 

 

 

 

 

 

 

 

869

 

Other

 

30

 

 

 

299

 

 

 

149

 

 

 

161

 

Changes in operating assets and liabilities:

 

 

 

 

 

 

 

Accounts receivable

 

(474

)

 

 

1,668

 

 

 

(424

)

 

 

2,345

 

Inventories

 

2,810

 

 

 

2,019

 

 

 

(2,493

)

 

 

(6,825

)

Prepaid expenses and other

 

(9,387

)

 

 

(2,587

)

 

 

(9,459

)

 

 

(7,566

)

Accounts payable, accrued and other liabilities

 

(10,964

)

 

 

17,710

 

 

 

(18,467

)

 

 

16,744

 

Net cash used in operating activities

 

(13,159

)

 

 

(12,526

)

 

 

(28,939

)

 

 

(33,159

)

Cash flows from investing activities:

 

 

 

 

 

 

 

Additions to property, plant and equipment

 

(1,798

)

 

 

(607

)

 

 

(3,687

)

 

 

(1,952

)

Additions to placement and evaluation units

 

(1,391

)

 

 

(1,239

)

 

 

(3,868

)

 

 

(3,245

)

Acquisition of intangibles

 

 

 

 

(3,250

)

 

 

 

 

 

(3,250

)

Proceeds from sale of assets

 

 

 

 

34,500

 

 

 

 

 

 

134,500

 

Net cash (used in) provided by investing activities

 

(3,189

)

 

 

29,404

 

 

 

(7,555

)

 

 

126,053

 

Cash flows from financing activities:

 

 

 

 

 

 

 

Repayment of long-term debt

 

 

 

 

 

 

 

 

 

 

(50,000

)

Payment of acquisition related contingent consideration

 

 

 

 

 

 

 

 

 

 

(10,000

)

Principal payments on finance arrangement

 

(58

)

 

 

 

 

 

(58

)

 

 

 

Proceeds from finance arrangement

 

6,310

 

 

 

 

 

 

6,310

 

 

 

 

Repurchase of common stock

 

 

 

 

 

 

 

(1,670

)

 

 

 

Proceeds from exercise of stock options and employee stock purchase plan

 

895

 

 

 

694

 

 

 

933

 

 

 

752

 

Net cash provided by (used) in financing activities

 

7,147

 

 

 

694

 

 

 

5,515

 

 

 

(59,248

)

Effect of exchange rate changes on cash and cash equivalents

 

(128

)

 

 

(17

)

 

 

(317

)

 

 

185

 

Increase (decrease) in cash and cash equivalents

 

(9,329

)

 

 

17,555

 

 

 

(31,296

)

 

 

33,831

 

Cash and cash equivalents at beginning of period

 

54,089

 

 

 

60,896

 

 

 

76,056

 

 

 

44,620

 

Cash and cash equivalents at end of period

$

44,760

 

 

$

78,451

 

 

$

44,760

 

 

$

78,451

 

 

Investors:

AngioDynamics, Inc.

Stephen Trowbridge, Executive Vice President & CFO

(518) 795-1408

[email protected]

Media:

Saleem Cheeks

Vice President, Communications

518-795-1174

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Oncology Medical Devices Health Health Technology General Health Cardiology

MEDIA:

Hope Bancorp Completes Merger With Territorial Bancorp

Hope Bancorp Completes Merger With Territorial Bancorp

LOS ANGELES–(BUSINESS WIRE)–
Hope Bancorp, Inc. (“Hope Bancorp”) (NASDAQ: HOPE), the holding company of Bank of Hope, today announced the completion of its merger with Honolulu-based Territorial Bancorp Inc. (“Territorial”), the holding company for Territorial Savings Bank. Effective as of April 2, 2025, Territorial Savings Bank will operate under the trade name Territorial Savings, a division of Bank of Hope, preserving the 100-plus year legacy of the Territorial brand, culture and commitment to local communities.

“We are excited to have completed this combination and to officially welcome Territorial customers and team members to the Bank of Hope family,” stated Kevin S. Kim, Chairman, President and Chief Executive Officer of Hope Bancorp. “With the addition of Territorial Savings, Bank of Hope has become the largest regional bank catering to multi-cultural customers across the continental United States and Hawaii.”

Pursuant to the merger agreement, Territorial shareholders have the right to receive 0.8048 shares of Hope Bancorp common stock in exchange for each share of Territorial common stock they own.

About Hope Bancorp, Inc.

Hope Bancorp, Inc. (NASDAQ: HOPE) is the holding company of Bank of Hope, the only regional Korean American bank in the United States with $17.05 billion in total assets as of December 31, 2024. With the addition of Territorial Savings, a division of Bank of Hope, effective April 2, 2025, the Company became the largest regional bank catering to multi-cultural customers across the continental United States and Hawaii. Headquartered in Los Angeles, the Bank provides a full suite of commercial, corporate and consumer loans, deposit and fee-based products and services, including commercial and commercial real estate lending, SBA lending, residential mortgage and other consumer lending; treasury management services, foreign currency exchange solutions, interest rate derivative products, and international trade financing, among others. The Bank operates 46 full-service branches in California, New York, New Jersey, Washington, Texas, Illinois, New York, New Jersey, Alabama, and Georgia under the Bank of Hope banner, and 29 branches in Hawaii under the Territorial Savings banner. The Bank also operates SBA loan production offices, commercial loan production offices, and residential mortgage loan production offices throughout the United States, and a representative office in Seoul, South Korea. Bank of Hope is a California-chartered bank, and its deposits are insured by the FDIC to the extent provided by law. Bank of Hope is an Equal Opportunity Lender. For additional information, please go to www.bankofhope.com for Bank of Hope and www.tsbhawaii.bank for Territorial Savings, a division of Bank of Hope. By including the foregoing website address link, Hope Bancorp does not intend to and shall not be deemed to incorporate by reference any material contained or accessible therein.

Forward-Looking Statements

Some statements in this news release may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements preceded by, followed by or that include the words “will,” “believes,” “expects,” “anticipates,” “intends,” “plans,” “estimates” or similar expressions. With respect to any such forward-looking statements, Hope Bancorp claims the protection provided for in the Private Securities Litigation Reform Act of 1995. These statements involve risks and uncertainties. Hope Bancorp’s actual results, performance or achievements may differ significantly from the results, performance or achievements expressed or implied in any forward-looking statements. Factors that may cause actual outcomes to differ from what is expressed or forecasted in these forward-looking statements include, among things: difficulties and delays in integrating Hope Bancorp and Territorial and achieving anticipated synergies, cost savings and other benefits from the transaction; higher than anticipated transaction costs; and deposit attrition, operating costs, customer loss and business disruption following the merger, including difficulties in maintaining relationships with employees and customers, may be greater than expected. Other risks and uncertainties include, but are not limited to: possible renewed deterioration in economic conditions in Hope Bancorp’s areas of operation or elsewhere; interest rate risk associated with volatile interest rates and related asset-liability matching risk; liquidity risks; risk of significant non-earning assets, and net credit losses that could occur, particularly in times of weak economic conditions or times of rising interest rates; the failure of or changes to assumptions and estimates underlying Hope Bancorp’s allowances for credit losses; potential increases in deposit insurance assessments and regulatory risks associated with current and future regulations; the outcome of any legal proceedings that may be instituted against Hope Bancorp; and risks from natural disasters. For additional information concerning these and other risk factors, see Hope Bancorp’s most recent Annual Report on Form 10-K. Hope Bancorp does not undertake, and specifically disclaims any obligation, to update any forward-looking statements to reflect the occurrence of events or circumstances after the date of such statements except as required by law.

For Hope Bancorp, Inc.

Julianna Balicka

EVP & Chief Financial Officer

213-235-3235

[email protected]

 

Angie Yang

SVP, Director of Investor Relations & Corporate Communications

213-251-2219

[email protected]

KEYWORDS: South Korea United States North America Asia Pacific California Hawaii

INDUSTRY KEYWORDS: Banking Professional Services Finance

MEDIA: